Lamine Mahaman Moustapha1,2, Rafiou Adamou3,4, Maman Laminou Ibrahim5, Mariama Abdoulaye Louis Padounou5, Abdoulaye Diallo6, David Courtin4, Jean Testa5, Jean Louis Abdourahim Ndiaye6. 1. Université Cheick Anta Diop-Dakar, Dakar, Sénégal. laminemahamanmoustapha@gmail.com. 2. Centre de Recherche Médicale et Sanitaire-Niamey, Niamey, Niger. laminemahamanmoustapha@gmail.com. 3. Laboratoire de Biochimie et de Biologie Moléculaire, Faculté des Sciences et Techniques, Université d'Abomey-Calavi, Abomey Calavi, Bénin. 4. MERIT UMR 216, Institut de Recherche pour le Développement, Université Paris Descartes, COMUE Sorbonne Paris Cité, Paris, 75006, France. 5. Centre de Recherche Médicale et Sanitaire-Niamey, Niamey, Niger. 6. Université Cheick Anta Diop-Dakar, Dakar, Sénégal.
Abstract
BACKGROUND: In endemic areas, children develop slowly and naturally anti-Plasmodium antibodies and become semi-immune. Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine + amodiaquine (SPAQ) is a new strategy to reduce malaria morbidity in West African young children. However, SMC may impact on the natural acquisition of anti-Plasmodium immunity. This paper evaluates the effect of SMC with SPAQ on antibody concentration in young children from Niger. METHODS: This research was conducted in areas benefitting from SMC since 2014 (Zinder district), without SMC (Dosso district), and with 1 year of SMC since 2016 (Gaya district). To assess the relationship between SMC and Plasmodium falciparum IgG antibody responses, the total antibody concentrations against two P. falciparum asexual stage vaccine candidate antigens, circumsporozoite protein (CSP) and glutamate-rich protein R2 (GLURP-R2), in children aged 3 to 59 months across the three areas were compared. Antibody concentrations are quantified using an enzyme-linked immunosorbent assay on the elution extracted from positive and negative malaria Rapid Diagnostic Test cassettes. RESULTS: The analysis concerns two hundred and twenty-nine children aged from 3 to 59 months: 71 in Zinder, 77 in Dosso, and 81 in Gaya. In Zinder (CSP = 17.5 µg/ml and GLURP-R2 = 14.3 µg/ml) median antibody concentration observed are higher than in Gaya (CSP = 7.7 µg/ml and GLURP-R2 = 6.5 µg/ml) and Dosso (CSP = 4.5 µg/ml and GLURP-R2 = 3.6 µg/ml) (p < 0.0001). CONCLUSION: The research reveals some evidences which show that seasonal malaria chemoprevention with SPAQ has an effect on blood stage antibody responses and pre-erythrocytic stage of P. falciparum infections in Niger. Increased antibody titres with increased SMC/SPAQ implementation. This contradicts hypothesis that SMC/SPAQ could reduce immunity to erythrocyte and liver-stage antigens. Further studies are necessary to provide better understanding of the SMC effect on malaria immunity.
BACKGROUND: In endemic areas, children develop slowly and naturally anti-Plasmodium antibodies and become semi-immune. Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine + amodiaquine (SPAQ) is a new strategy to reduce malaria morbidity in West African young children. However, SMC may impact on the natural acquisition of anti-Plasmodium immunity. This paper evaluates the effect of SMC with SPAQ on antibody concentration in young children from Niger. METHODS: This research was conducted in areas benefitting from SMC since 2014 (Zinder district), without SMC (Dosso district), and with 1 year of SMC since 2016 (Gaya district). To assess the relationship between SMC and Plasmodium falciparum IgG antibody responses, the total antibody concentrations against two P. falciparum asexual stage vaccine candidate antigens, circumsporozoite protein (CSP) and glutamate-rich protein R2 (GLURP-R2), in children aged 3 to 59 months across the three areas were compared. Antibody concentrations are quantified using an enzyme-linked immunosorbent assay on the elution extracted from positive and negative malaria Rapid Diagnostic Test cassettes. RESULTS: The analysis concerns two hundred and twenty-nine children aged from 3 to 59 months: 71 in Zinder, 77 in Dosso, and 81 in Gaya. In Zinder (CSP = 17.5 µg/ml and GLURP-R2 = 14.3 µg/ml) median antibody concentration observed are higher than in Gaya (CSP = 7.7 µg/ml and GLURP-R2 = 6.5 µg/ml) and Dosso (CSP = 4.5 µg/ml and GLURP-R2 = 3.6 µg/ml) (p < 0.0001). CONCLUSION: The research reveals some evidences which show that seasonal malaria chemoprevention with SPAQ has an effect on blood stage antibody responses and pre-erythrocytic stage of P. falciparum infections in Niger. Increased antibody titres with increased SMC/SPAQ implementation. This contradicts hypothesis that SMC/SPAQ could reduce immunity to erythrocyte and liver-stage antigens. Further studies are necessary to provide better understanding of the SMC effect on malaria immunity.
Entities:
Keywords:
Antibody; CSP; GLURP-R2; Immunity; P. falciparum; Seasonal malaria chemoprevention
Authors: David R Cavanagh; Patrice M Dubois; Andreas Holtel; Agnes Kisser; Odile Leroy; Emily Locke; Vasee S Moorthy; Edmond J Remarque; Ya Ping Shi Journal: Vaccine Date: 2011-02-04 Impact factor: 3.641
Authors: David Schellenberg; Clara Menendez; John J Aponte; Elizeus Kahigwa; Marcel Tanner; Hassan Mshinda; Pedro Alonso Journal: Lancet Date: 2005 Apr 23-29 Impact factor: 79.321
Authors: Amrish Baidjoe; Will Stone; Ivo Ploemen; Shehu Shagari; Lynn Grignard; Victor Osoti; Euniah Makori; Jennifer Stevenson; Simon Kariuki; Colin Sutherland; Robert Sauerwein; Jonathan Cox; Chris Drakeley; Teun Bousema Journal: Malar J Date: 2013-08-02 Impact factor: 2.979
Authors: Rebecca F Grais; Ibrahim M Laminou; Lynda Woi-Messe; Rockyath Makarimi; Seidou H Bouriema; Celine Langendorf; Alfred Amambua-Ngwa; Umberto D'Alessandro; Philippe J Guérin; Thierry Fandeur; Carol H Sibley Journal: Malar J Date: 2018-02-27 Impact factor: 2.979